About
Oral Carbon Monoxide Therapeutics
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
65
By Phase
PHASE2: 1PHASE1/PHASE2: 1PHASE1: 1
By Status
NOT_YET_RECRUITING: 1RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT07005180Lead Sponsor
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
PHASE2Not yet recruiting
36 participants
Started: Aug 31, 2025 · Completed: Mar 31, 2026
NCT06144749Lead Sponsor
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
PHASE1/PHASE2Recruiting
9 participants
Started: Feb 15, 2025 · Completed: Dec 31, 2025
NCT03926819Lead Sponsor
A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
PHASE1Completed
20 participants
Started: Jul 25, 2022 · Completed: Apr 26, 2023
Funding History (1)
D
Sep 26, 2023
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...